Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | MITF | O75030 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.42 |
| ▸ | FABP7 | O15540 | 1/20 | 0.42 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL119110 | 1.00 | KMT2A (0.53) | KMT2AEPHX2NR1H4OPRD1RAB9A | |
| SCHEMBL29618948 | 1.00 | KMT2A (0.53) | KMT2AEPHX2NR1H4OPRD1RAB9A | |
| SCHEMBL7828581 | 0.93 | KMT2A (0.47) | KMT2AEPHX2NR1H4OPRD1RAB9A | |
| Benzoic Acid SCHEMBL27028192 | 0.91 | KMT2A (0.56) | KMT2AEPHX2OPRD1FABP7FABP5 | |
| SCHEMBL22498215 | 0.90 | KMT2A (0.55) | KMT2AEPHX2OPRD1FABP7FABP5 | |
| SCHEMBL5551698 | 0.88 | KMT2A (0.49) | KMT2AEPHX2OPRD1RAB9ANPC1 | |
| SCHEMBL3064762 | 0.88 | EPHX2 (0.49) | KMT2AEPHX2HIF1A | |
| SCHEMBL1855344 | 0.88 | EPHX2 (0.53) | KMT2AEPHX2NR1H4 | |
| SCHEMBL14452747 | 0.87 | EPHX2 (0.48) | KMT2AEPHX2OPRD1FABP7FABP5 | |
| SCHEMBL3177417 | 0.87 | KMT2A (0.62) | KMT2AEPHX2OPRD1FABP7FABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250332300-A1 | HER2 TARGETING CYCLIC PEPTIDES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2025-10-30 | — | — | US | disclosed |
| EP-4003959-A1 | TARGETED RADIOPHARMACEUTICALS FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | Bayer AS (NO) | 2022-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250332300-A1 | HER2 TARGETING CYCLIC PEPTIDES AND CONJUGATES THEREOF | ERBB2, EGFR, ERBB3 | KMT2A 3524/4885EPHX2 2858/4885NR1H4 437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.